Medical University of Vienna

The 18th Cancer Research Run at MedUni Vienna aims to run 45,000 km, one for each new cancer diagnosis in Austria annually. Participants can run on-site or remotely, with donations supporting cancer research projects. Cancer mortality is declining due to advances in medicine, and donations fund 14 ongoing projects focusing on precision medicine.

The Cancer School at Comprehensive Cancer Center Vienna empowers patients through knowledge, starting Oct 1, 2024. Focusing on 'Patient Engagement, Involvement, Empowerment,' it offers monthly free lectures and a Cancer Prevention Day on Feb 15, 2025. Registration at www.cancerschool.at.

The TRIPOD+AI update provides harmonised guidance for reporting prediction model studies, superseding TRIPOD 2015, to accommodate AI and machine learning methods. The new 27-item checklist aims for complete, accurate, and transparent reporting, facilitating study appraisal and model implementation.

AngioDynamics launches RECOVER-AV trial to evaluate AlphaVac F18⁸⁵ System for acute, intermediate-risk PE in Europe, following successful APEX-AV study in the U.S. The trial aims to assess safety and efficacy, with primary endpoints focusing on RV/LV ratio reduction and Major Adverse Events incidence.

MEDSIR, in collaboration with Oncoclinicas & Co., presented 12 studies at the European Society for Medical Oncology (ESMO) congress, including the ABIGAIL study on HR+/HER2- advanced breast cancer and the PECATI study on advanced thymic tumors, demonstrating significant progress in personalized treatments and therapeutic options for difficult-to-treat cancers.

TiNivo-2 trial results show no improvement in outcomes for RCC patients when adding nivolumab to tivozanib vs. tivozanib alone after ICI therapy progression, with median PFS of 5.7 months vs. 7.4 months, respectively. The study suggests ICI rechallenge should generally be discouraged.